Figure 5. The IKKε/TBK1 inhibitor Amlexanox sensitizes β-adrenergic agonist-stimulated lipolysis in white adipose tissue in diet-induced obese mice.
(A) Fold increase in serum FFA (left panel) and glycerol (right panel) levels 15 min after CL-316,243 injection in ND- or HFD-fed mice treated with amlexanox or vehicle control for 4 days. n = 7 mice per group. *p<0.05. (B) Glycerol release from ex vivo epididymal (left panel) and inguinal (right panel) WATs after 1 hr pretreatment with amlexanox or vehicle. CL-316,243 treatment was started at time zero. n = 6, 3 WAT pieces × 2 mice. *P<0.05. (C) Immunoblots in inguinal WAT lysates from Figure 5B after 60 min of CL-316,243 treatment. (D) cAMP levels in epididymal WAT 20 min after CL-316,243 (CL) or saline control injection in HFD-fed mice treated with amlexanox or vehicle control for 4 days. n = 2 mice per saline-treated group and n = 3 mice per CL-316,324-treated group. *p<0.05. (E) Immunoblots in epididymal WAT 5 min after CL-316,243 or saline control injection in HFD-fed mice treated with amlexanox or vehicle control for 4 days. (F) Relative oxygen comsumption of mice in each treatment group. n = 7 for the vehicle-treated group, n = 5 for the amlexanox-treated group. *P<0.05 (Student’s t test).